NEXTGENJANE INC
Oakland, CA · Founded 2014 · CIK 0001668977 · Medtech · Private
Longitudinal molecular database and biomarker platform tracking menstrual cycle biochemistry in women
nextgenjane.com →- Grants
- $4.8M
- 6 awards
- Sector median: 1
- Raised
- $19M
- 4 Form D · Oct 2023
- 36 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,217,234 | |
| Private capital raised | Form D · SEC | $8,745,825 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | $267,669 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | $1,108,476 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | $1,510,006 | |
| Private capital raised | Form D · SEC | $1,500,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | $401,530 | |
| Private capital raised | Form D · SEC | $7,022,010 | |
| Federal grant | Department of Health and Human Services · Phase II · Performance evaluation of a non-invasive menstrual test for endometriosis in infertility patients | $759,944 | |
| Federal grant | Department of Health and Human Services · Phase II · Performance evaluation of a non-invasive menstrual test for endometriosis in infertility patients | $714,095 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1312 | INANOVATE INC | — | $13M |
| 1313 | Optain Health, Inc. | — | $31M |
| 1314 | FRESHAIR SENSOR CORPORATION | — | $32M |
| 1315 | NEXTGENJANE INC | — | $19M |
| 1316 | Etiometry Inc. | — | $8.2M |
| 1317 | AGIL THERAPEUTICS, INC. | — | — |
| 1318 | BennuBio Inc | — | $6.8M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Stephen GireDirector · Executive Officer
- STEPHEN GIREDirector · Executive Officer
- Deborah KilpatrickDirector
- DEBORAH KILPATRICKDirector
- Adam SharkawyDirector
- ADAM SHARKAWYDirector
- Ridhi TariyalDirector · Executive Officer
- RIDHI TARIYALDirector · Executive Officer
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.